Chemical modification of interleukin-10 with mannose 6-phosphate groups yields a liver-selective cytokine

Drug Metabolism and Disposition

Volumn 35, Issue 5, 2007, Pages 814-821

  Rachmawati, Heni ^a   Reker Smit, Catharina ^a   Lub de Hooge, Marjolijn N ^b   Van Loenen Weemaes, Annemiek ^a   Poelstra, Klaas ^a   Beljaars, Leonie ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MANNOSE 6 PHOSPHATE; SOMATOMEDIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; IMMUNOTHERAPY; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STELLATE CELL;

ANIMALS; BLOTTING, WESTERN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; INTERLEUKIN-10; IODINE RADIOISOTOPES; KIDNEY; LIPOPOLYSACCHARIDES; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MACROPHAGES; MALE; MANNOSEPHOSPHATES; MOLECULAR STRUCTURE; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 34247347825     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013490     Document Type: Article

References (43)

1. Adams G, Vessillier S, Dreja H, and Chernajovsky Y (2003) Targeting cytokines to inflammation sites. Nat Biotechnol 21:1314-1320.
2. Adrian JE, Poelstra K, Scherphof GL, Molema G, Meijer DK, Reker-Smit C, Morselt HW, and Kamps JA (2006) Interaction of targeted liposomes with primary cultured hepatic stellate cells: involvement of multiple receptor systems. J Hepatol 44:560-567.
3. Andersen SR, Lambrecht LJ, Swan SK, Cutler DL, Radwanski E, Affrime MB, and Garaud JJ (1999) Disposition of recombinant human interleukin-10 in subjects with various degrees of renal function. J Clin Pharmacol 39:1015-1020.
4. Arai T, Abe K, Matsuoka H, Yoshida M, Mori M, Goya S, Kida H, Nishino K, Osaki T, Tachibana I, et al. (2000) Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol 278:L914-L922.
5. Beljaars L, Molema G, Schuppan D, Geerts A, De Bleser PJ, Weert B, Meijer DK, and Poelstra K (2000) Successful targeting of albumin to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J Biol Chem 275:12743-12751.
6. Beljaars L, Molema G, Weert B, Bonnema H, Olinga P, Groothuis GM, Meijer DK, and Poelstra K (1999) Albumin modified with mannose 6-phosphate: a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 29:1486-1493.
7. Beljaars L, Olinga P, Molema G, De Bleser P, Geerts A, Groothuis GM, Meijer DK, and Poelstra K (2001) Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P(28)-HSA). Liver 21:320-328.
8. Bentala H, Verweij WR, Huizinga-van der Vlag A, Miek Van Loenen-Weemaes AM, Meijer DK, and Poelstra K (2002) Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 18:561-566.
9. Brown LR (2005) Commercial challenges of protein drug delivery. Expert Opin Drug Deliv 2:29-42.
10. Choi YK, Kim YJ, Park HS, Choi K, Paik SG, Lee YI, and Park JG (2003) Suppression of glomerulosclerosis by adenovirus-mediated IL-10 expression in the kidney. Gene Ther 10:559-568.
11. Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, and Corti A (2005) Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res 65:2906-2913.
12. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, and Corti A (2000) Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to amino-peptidase N (CD13). Nat Biotechnol 18:1185-1190.
13. De Bleser PJ, Jannes P, Buul-Offers SC, Hoogerbrugge CM, van Schravendijk CF, Niki T, Rogiers V, van den Brande JL, Wisse E, and Geerts A (1995) Insulinlike growth factor-II/mannose 6-phosphate receptor is expressed on CCl4-exposed rat fat-storing cells and facilitates activation of latent transforming growth factor-beta in cocultures with sinusoidal endothelial cells. Hepatology 21:1429-1437.
14. Geerts A (2001) History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21:311-335.
15. 131I labelled human growth hormone of high specific radioactivity. Biochem J 89:114-123.
16. Greupink R, Bakker HI, van Goor H, de Borst MH, Beljaars L, and Poelstra K (2006) Mannose-6-phosphate/insulin-like growth factor-II receptors may represent a target for the selective delivery of mycophenolic acid to fibrogenic cells. Pharm Res (NY) 23:1827-1834.
17. Harris JM and Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
18. Hung KS, Lee TH, Chou WY, Wu CL, Cho CL, Lu CN, Jawan B, and Wang CH (2005) Interleukin-10 gene therapy reverses thioacetamide-induced liver fibrosis in mice. Biochem Biophys Res Commun 336:324-331.
19. Kountouras J, Billing BH, and Scheuer PJ (1984) Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 65:305-311.
20. Mather SJ and Ward BC (1987) High efficiency iodination of monoclonal antibodies for radiotherapy. J Nucl Med 28:1034-1036.
21. Mathurin P, Xiong S, Kharbanda KK, Veal N, Miyahara T, Motomura K, Rippe RA, Bachem MG, and Tsukamoto H (2002) IL-10 receptor and coreceptor expression in quiescent and activated hepatic stellate cells. Am J Physiol 282:G981-G990.
22. Moore KW, Waal Malefyt R, Coffman RL, and O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765.
23. Nelson DR, Lauwers GY, Lau JY, and Davis GL (2000) Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 118:655-660.
24. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, Cabrera R, Liu C, and Davis GL (2003) Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 38:859-868.
25. Penichet ML and Morrison SL (2001) Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 248:91-101.
26. Pinzani M, Rombouts K, and Colagrande S (2005) Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42 (Suppl 1):S22-S36.
27. Rachmawati H, Beljaars L, Reker-Smit C, Van Loenen-Weemaes AM, Hagens WI, Meijer DK, and Poelstra K (2004a) Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis. Pharm Res (NY) 21:2072-2078.
28. Rachmawati H, Poelstra K, and Beljaars L (2004b) The use of cytokines and modified cytokines as therapeutic agents, in Recent Research Developments in Immunology, vol 6 (Pandalai SG ed) pp 191-217, Research Sign Post, Kerala, India.
29. Reineke U, Sabat R, Volk HD, and Schneider-Mergener J (1998) Mapping of the interleukin-10/interleukin-10 receptor combining site. Protein Sci 7:951-960.
30. Reitamo S, Remitz A, Tamai K, and Uitto J (1994) Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Investig 94:2489-2492.
31. Ricke WA, Smith GW, and Smith MF (2002) Matrix metalloproteinase expression and activity following prostaglandin F(2 alpha)-induced luteolysis. Biol Reprod 66:685-691.
32. Rockey DC, Boyles JK, Gabbiani G, and Friedman SL (1992) Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 24:193-203.
33. Schaefer B, Rivas-Estilla AM, Meraz-Cruz N, Reyes-Romero MA, Hernandez-Nazara ZH, Dominguez-Rosales JA, Schuppan D, Greenwel P, and Rojkind M (2003) Reciprocal modulation of matrix metalloproteinase-13 and type I collagen genes in rat hepatic stellate cells. Am J Pathol 162:1771-1780.
34. Schneiderhan W, Schmid-Kotsas A, Zhao J, Grunert A, Nussler A, Weidenbach H, Menke A, Schmid RM, Adler G, and Bachem MG (2001) Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology 34:729-737.
35. Schrama D, Reisfeld RA, and Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147-159.
36. Swart PJ, Beljaars E, Smit C, Pasma A, Schuitemaker H, and Meijer DK (1996) Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. J Drug Target 4:109-116.
37. Terpstra V, van Amersfoort ES, van Velzen AG, Kuiper J, and Van Berkel TJ (2000) Hepatic and extrahepatic scavenger receptors: function in relation to disease. Arterioscler Thromb Vasc Biol 20:1860-1872.
38. Thompson KC, Trowern A, Fowell A, Marathe M, Haycock C, Arthur MJ, and Sheron N (1998) Primary rat and mouse hepatic stellate cells express the macrophage inhibitor cytokine interleukin-10 during the course of activation in vitro. Hepatology 28:1518-1524.
39. Vaillant B, Chiaramonte MG, Cheever AW, Soloway PD, and Wynn TA (2001) Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol 167:7017-7026.
40. Veronese FM and Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451-1458.
41. Wang SC, Ohata M, Schrum L, Rippe RA, and Tsukamoto H (1998) Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem 273:302-308.
42. Weiner JA, Chen A, and Davis BH (1998) E-box-binding repressor is down-regulated in hepatic stellate cells during up-regulation of mannose 6-phosphate/insulin-like growth factor-II receptor expression in early hepatic fibrogenesis. J Biol Chem 273:15913-15919.
43. Yamamoto T, Eckes B, and Krieg T (2001) Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1. Biochem Biophys Res Commun 281:200-205.